Figure S1. Optimization of LPS concentration. Mouse macrophages in 24-wells were preincubated with 5 ng/μl human anti-TLR4 IgG2 for 2 h and then stimulated with different concentrations of LPS. mRNA expression levels of (A) *TNF-α*, (B) *IFN-β* and (C) *IL-6* were determined by reverse transcription-quantitative PCR and normalized to the internal control, *β-actin*. Data are presented as the mean ± SD. N=3. *P<0.05, **P<0.01 vs. LPS control. LPS, lipopolysaccharide; TLR4, Toll-like receptor 4; L, LPS; A, human anti-TLR4 IgG2; IL, interleukin; IFN-β, interferon-β; TNF-α, tumor necrosis factor-α.



Figure S2. Human anti-TLR4 IgG2 inhibits LPS-induced sepsis in mice by decreasing serum proinflammatory cytokine levels. Mice were intravenously injected with human anti-TLR4 IgG2 (15 μg/g) or an equal dose of PBS at 2 h before exposure to LPS (15 μg/g). At 2 or 4 h after the LPS challenge, serum concentrations of (A) TNF-α, (B) IFN-β and (C) IL-6 were determined by ELISA. N=3. ***P<0.001 vs. LPS control. LPS, lipopolysaccharide; TLR4, Toll-like receptor 4; L, LPS; A, human anti-TLR4 IgG2; IL, interleukin; IFN-β, interferon-β; TNF-α, tumor necrosis factor-α.